{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:27:38Z","timestamp":1793406458625,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multi-drug resistant Gram-negative pathogens are increasingly difficult-to-treat perpetrators of infections. New, innovative, and more multifaceted therapies for the treatment of multi-drug resistant strains are thus urgent to hinder further drug resistance and mitigate deadly, untreatable infections. Our study aimed to investigate the efficacy of cefiderocol against Gram-negative aerobic bacteria alone and in combination with phages. The minimum inhibitory concentration (MIC)\u00a0of cefiderocol was determined using the microdilution broth method, while the minimum biofilm bactericidal concentration was assessed using isothermal microcalorimetry. The combined effect of cefiderocol and phages was evaluated using colony-forming unit counts. Results demonstrated a notable antibacterial effect of cefiderocol, with 83.4% of tested strains exhibiting susceptibility. When combined with phages, the MIC of cefiderocol was reduced by 2\u201364-fold, indicating a synergistic interaction between the two agents. Furthermore, the combination therapy showed enhanced efficacy against biofilm compared to monotherapy with either cefiderocol or phages alone, leading to complete biofilm elimination in certain cases. This study highlights the potential of combining cefiderocol with phages as a strategy to combat multi-drug resistant Gram-negative bacterial infections. The observed synergy suggests that this combination therapy could improve treatment outcomes and help address the challenges of antibiotic resistance and biofilm-associated infections.<\/jats:p>","DOI":"10.1038\/s41598-025-01704-w","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T17:49:08Z","timestamp":1747417748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro activity of cefiderocol against Gram-negative aerobic bacilli in planktonic and biofilm form\u2013alone and in combination with bacteriophages"],"prefix":"10.1038","volume":"15","author":[{"given":"Rima Fanaei","family":"Pirlar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nexhmije","family":"Halili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Travnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Trampuz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Karbysheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"11","key":"1704_CR1","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/antibiotics12111590","volume":"12","author":"A Gauba","year":"2023","unstructured":"Gauba, A. & Rahman, K. M. Evaluation of antibiotic resistance mechanisms in gram-negative bacteria. Antibiotics 12(11), 1590 (2023).","journal-title":"Antibiotics"},{"key":"1704_CR2","doi-asserted-by":"crossref","unstructured":"Assefa, M. & Amare, A. Biofilm-associated multi-drug resistance in hospital-acquired infections: A review. Infect. Drug Resist. 2022:5061\u20135068 .","DOI":"10.2147\/IDR.S379502"},{"issue":"2","key":"1704_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/cc9997","volume":"15","author":"M Bassetti","year":"2011","unstructured":"Bassetti, M., Ginocchio, F. & Mikulska, M. New treatment options against gram-negative organisms. Crit. Care 15(2), 215 (2011).","journal-title":"Crit. Care"},{"issue":"3","key":"1704_CR4","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3390\/pathogens11030292","volume":"11","author":"L Shrestha","year":"2022","unstructured":"Shrestha, L., Fan, H-M., Tao, H-R. & Huang, J-D. Recent strategies to combat biofilms using antimicrobial agents and therapeutic approaches. Pathogens 11(3), 292 (2022).","journal-title":"Pathogens"},{"issue":"9","key":"1704_CR5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jiph.2022.07.006","volume":"15","author":"S Corcione","year":"2022","unstructured":"Corcione, S. et al. Cefiderocol use in gram negative infections with limited therapeutic options: Is combination therapy the key? J. Infect. Public Health 15(9), 975\u2013979 (2022).","journal-title":"J. Infect. Public Health"},{"key":"1704_CR6","doi-asserted-by":"publisher","first-page":"896971","DOI":"10.3389\/fphar.2022.896971","volume":"13","author":"C Wang","year":"2022","unstructured":"Wang, C., Yang, D., Wang, Y. & Ni, W. Cefiderocol for the treatment of multidrug-resistant Gram-negative bacteria: A systematic review of currently available evidence. Front. Pharmacol. 13, 896971 (2022).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"1704_CR7","doi-asserted-by":"publisher","first-page":"01194","DOI":"10.1128\/aac","volume":"65","author":"CA Pybus","year":"2021","unstructured":"Pybus, C. A., Felder-Scott, C., Obuekwe, V. & Greenberg, D. E. Cefiderocol retains antibiofilm activity in multidrug-resistant gram-negative pathogens. Antimicrob. Agents Chemother. 65(2), 01194\u201301120. https:\/\/doi.org\/10.1128\/aac (2021).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"1704_CR8","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1128\/AAC.01405-16","volume":"60","author":"A Ito","year":"2016","unstructured":"Ito, A. et al. Siderophore cephalosporin Cefiderocol utilizes ferric iron transporter systems for antibacterial activity against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 60(12), 7396\u20137401 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"1704_CR9","doi-asserted-by":"publisher","first-page":"dlae183","DOI":"10.1093\/jacamr\/dlae183","volume":"6","author":"K Kocer","year":"2024","unstructured":"Kocer, K., Boutin, S., Moll, M. & Nurjadi, D. Investigation of Cefiderocol resistance prevalence and resistance mechanisms in carbapenem-resistant Pseudomonas aeruginosa, Germany 2019\u201321. JAC-Antimicrobial Resist. 6(6), dlae183 (2024).","journal-title":"JAC-Antimicrobial Resist."},{"issue":"10","key":"1704_CR10","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.3390\/pathogens10101258","volume":"10","author":"B Ghebremedhin","year":"2021","unstructured":"Ghebremedhin, B. & Ahmad-Nejad, P. In-Vitro efficacy of Cefiderocol in carbapenem-non-susceptible gram-negative bacilli of different genotypes in sub-region of North rhine Westphalia. Ger. Pathogens. 10(10), 1258 (2021).","journal-title":"Ger. Pathogens"},{"issue":"1","key":"1704_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/20905068.2020.1851441","volume":"57","author":"K Ssekatawa","year":"2021","unstructured":"Ssekatawa, K. et al. A review of phage mediated antibacterial applications. Alexandria J. Med. 57(1), 1\u201320 (2021).","journal-title":"Alexandria J. Med."},{"issue":"5","key":"1704_CR12","first-page":"703","volume":"215","author":"F Oechslin","year":"2017","unstructured":"Oechslin, F. et al. Synergistic interaction between phage therapy and antibiotics clears Pseudomonas aeruginosa infection in endocarditis and reduces virulence. J. Infect. Dis. 215(5), 703\u2013712 (2017).","journal-title":"J. Infect. Dis."},{"issue":"5","key":"1704_CR13","doi-asserted-by":"publisher","first-page":"570","DOI":"10.3390\/antibiotics11050570","volume":"11","author":"C Liu","year":"2022","unstructured":"Liu, C., Hong, Q., Chang, R. Y. K., Kwok, P. C. L. & Chan, H-K. Phage\u2013antibiotic therapy as a promising strategy to combat multidrug-resistant infections and to enhance antimicrobial efficiency. Antibiotics 11(5), 570 (2022).","journal-title":"Antibiotics"},{"issue":"4","key":"1704_CR14","doi-asserted-by":"publisher","first-page":"01462","DOI":"10.1128\/mbio","volume":"11","author":"C Gu Liu","year":"2020","unstructured":"Gu Liu, C. et al. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. MBio 11(4), 01462\u201301420. https:\/\/doi.org\/10.1128\/mbio (2020).","journal-title":"MBio"},{"issue":"4","key":"1704_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.tim.2015.12.011","volume":"24","author":"C Torres-Barcel\u00f3","year":"2016","unstructured":"Torres-Barcel\u00f3, C. & Hochberg, M. E. Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 24(4), 249\u2013256 (2016).","journal-title":"Trends Microbiol."},{"issue":"8","key":"1704_CR16","doi-asserted-by":"publisher","first-page":"e799","DOI":"10.1371\/journal.pone.0000799","volume":"2","author":"AM Comeau","year":"2007","unstructured":"Comeau, A. M., T\u00e9tart, F., Trojet, S. N., Pr\u00e8re, M-F. & Krisch, H. M. Phage-antibiotic synergy (PAS): \u03b2-lactam and quinolone antibiotics stimulate virulent phage growth. Plos One 2(8), e799 (2007).","journal-title":"Plos One"},{"issue":"1","key":"1704_CR17","doi-asserted-by":"publisher","first-page":"26717","DOI":"10.1038\/srep26717","volume":"6","author":"BK Chan","year":"2016","unstructured":"Chan, B. K. et al. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6(1), 26717 (2016).","journal-title":"Sci. Rep."},{"issue":"6","key":"1704_CR18","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","volume":"10","author":"DF Bavaro","year":"2021","unstructured":"Bavaro, D. F. et al. Cefiderocol-based combination therapy for difficult-to-treat gram-negative severe infections: Real-life case series and future perspectives. Antibiotics 10(6), 652 (2021).","journal-title":"Antibiotics"},{"issue":"Supplement_7","key":"1704_CR19","doi-asserted-by":"publisher","first-page":"S519","DOI":"10.1093\/cid\/ciz823","volume":"69","author":"RA Bonomo","year":"2019","unstructured":"Bonomo, R. A. Cefiderocol: A novel siderophore cephalosporin defeating carbapenem-resistant pathogens. Clin. Infect. Dis. 69(Supplement_7), S519\u2013S520 (2019).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"1704_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ijantimicag.2018.10.007","volume":"53","author":"KM Kazmierczak","year":"2019","unstructured":"Kazmierczak, K. M. et al. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative Bacilli, including Serine carbapenemase-and metallo-\u03b2-lactamase-producing isolates (SIDERO-WT-2014 Study). Int. J. Antimicrob. Agents. 53(2), 177\u2013184 (2019).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"1704_CR21","unstructured":"2388. Efficacy of Humanized Cefiderocol Exposures Over 72 Hours against a Diverse Group of Gram-Negative Isolates in the Neutropenic Murine Thigh (Oxford University Press, 2018)."},{"issue":"8","key":"1704_CR22","first-page":"801","volume":"24","author":"IJ Schalk","year":"2018","unstructured":"Schalk, I. J. Siderophore-antibiotic conjugates: Exploiting iron uptake to deliver drugs into bacteria. Clin. Microbiol. Infect. Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis. 24(8), 801\u2013802 (2018).","journal-title":"Clin. Microbiol. Infect. Official Publication Eur. Soc. Clin. Microbiol. Infect. Dis."},{"issue":"6","key":"1704_CR23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","volume":"11","author":"S Karakonstantis","year":"2022","unstructured":"Karakonstantis, S., Rousaki, M. & Kritsotakis, E. I. Cefiderocol: Systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance. Antibiotics 11(6), 723 (2022).","journal-title":"Antibiotics"},{"issue":"3","key":"1704_CR24","doi-asserted-by":"publisher","first-page":"dlac046","DOI":"10.1093\/jacamr\/dlac046","volume":"4","author":"PJ Simner","year":"2022","unstructured":"Simner, P. J. et al. Combination of phage therapy and Cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis. JAC-Antimicrobial Resist. 4(3), dlac046 (2022).","journal-title":"JAC-Antimicrobial Resist."},{"issue":"10","key":"1704_CR25","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.3390\/pharmaceutics14102216","volume":"14","author":"R Fanaei Pirlar","year":"2022","unstructured":"Fanaei Pirlar, R. et al. Novel Stenotrophomonas maltophilia bacteriophage as potential therapeutic agent. Pharmaceutics 14(10), 2216 (2022).","journal-title":"Pharmaceutics"},{"key":"1704_CR26","doi-asserted-by":"crossref","unstructured":"Altamirano, F. L. G. et al. Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study. EBioMedicine 2022;80.","DOI":"10.1016\/j.ebiom.2022.104045"},{"issue":"1","key":"1704_CR27","doi-asserted-by":"publisher","first-page":"e0168615","DOI":"10.1371\/journal.pone.0168615","volume":"12","author":"WN Chaudhry","year":"2017","unstructured":"Chaudhry, W. N. et al. Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. Plos One. 12(1), e0168615 (2017).","journal-title":"Plos One"},{"issue":"3","key":"1704_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1128\/CMR.05041-11","volume":"25","author":"PD Tamma","year":"2012","unstructured":"Tamma, P. D., Cosgrove, S. E. & Maragakis, L. L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 25(3), 450\u2013470 (2012).","journal-title":"Clin. Microbiol. Rev."},{"issue":"5","key":"1704_CR29","doi-asserted-by":"publisher","first-page":"e02347","DOI":"10.1128\/spectrum.02347-22","volume":"10","author":"S Stracquadanio","year":"2022","unstructured":"Stracquadanio, S. et al. Acinetobacter baumannii and cefiderocol, between Cidality and adaptability. Microbiol. Spectr. 10(5), e02347\u2013e02322 (2022).","journal-title":"Microbiol. Spectr."},{"issue":"8","key":"1704_CR30","doi-asserted-by":"publisher","first-page":"02171","DOI":"10.1128\/aac","volume":"65","author":"EK McCreary","year":"2021","unstructured":"McCreary, E. K., Heil, E. L. & Tamma, P. D. New perspectives on antimicrobial agents: Cefiderocol. Antimicrob. Agents Chemother. 65(8), 02171\u201302120. https:\/\/doi.org\/10.1128\/aac (2021).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"9","key":"1704_CR31","doi-asserted-by":"publisher","first-page":"e106628","DOI":"10.1371\/journal.pone.0106628","volume":"9","author":"C Torres-Barcel\u00f3","year":"2014","unstructured":"Torres-Barcel\u00f3, C. et al. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. Plos One 9(9), e106628 (2014).","journal-title":"Plos One"},{"key":"1704_CR32","doi-asserted-by":"publisher","first-page":"561097","DOI":"10.3389\/fmicb.2020.01434","volume":"11","author":"P Manohar","year":"2020","unstructured":"Manohar, P. et al. Secondary bacterial infections during pulmonary viral disease: phage therapeutics as alternatives to antibiotics? Front. Microbiol. 11, 561097 (2020).","journal-title":"Front. Microbiol."},{"issue":"3","key":"1704_CR33","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4292\/wjgpt.v8.i3.162","volume":"8","author":"DM Lin","year":"2017","unstructured":"Lin, D. M., Koskella, B. & Lin, H. C. Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 8(3), 162 (2017).","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"issue":"1","key":"1704_CR34","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1146\/annurev.micro.55.1.437","volume":"55","author":"WC Summers","year":"2001","unstructured":"Summers, W. C. Bacteriophage therapy. Annual Reviews Microbiol. 55(1), 437\u2013451 (2001).","journal-title":"Annual Reviews Microbiol."},{"issue":"24","key":"1704_CR35","doi-asserted-by":"publisher","first-page":"12538","DOI":"10.1074\/jbc.R115.707547","volume":"291","author":"JS Gunn","year":"2016","unstructured":"Gunn, J. S., Bakaletz, L. O. & Wozniak, D. J. What\u2019s on the outside matters: The role of the extracellular polymeric substance of Gram-negative biofilms in evading host immunity and as a target for therapeutic intervention. J. Biol. Chem. 291(24), 12538\u201312546 (2016).","journal-title":"J. Biol. Chem."},{"issue":"6","key":"1704_CR36","doi-asserted-by":"publisher","first-page":"e0235093","DOI":"10.1371\/journal.pone.0235093","volume":"15","author":"R Fanaei Pirlar","year":"2020","unstructured":"Fanaei Pirlar, R. et al. Combinatorial effects of antibiotics and enzymes against dual-species Staphylococcus aureus and Pseudomonas aeruginosa biofilms in the wound-like medium. Plos One 15(6), e0235093 (2020).","journal-title":"Plos One"},{"key":"1704_CR37","doi-asserted-by":"crossref","unstructured":"Davis, C. M., McCutcheon, J. G. & Dennis, J. J. Aztreonam lysine increases the activity of phages E79 and phiKZ against Pseudomonas aeruginosa PA01. Microorganisms. 9(1), 152. (2021).","DOI":"10.3390\/microorganisms9010152"},{"issue":"1","key":"1704_CR38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.resmic.2012.08.008","volume":"164","author":"P Knezevic","year":"2013","unstructured":"Knezevic, P., Curcin, S., Aleksic, V., Petrusic, M. & Vlaski, L. Phage-antibiotic synergism: A possible approach to combatting Pseudomonas aeruginosa. Res. Microbiol. 164(1), 55\u201360 (2013).","journal-title":"Res. Microbiol."},{"issue":"22","key":"1704_CR39","doi-asserted-by":"publisher","first-page":"e02085","DOI":"10.1128\/AEM.02085-18","volume":"84","author":"M Kim","year":"2018","unstructured":"Kim, M. et al. Phage-antibiotic synergy via delayed Lysis. Appl. Environ. Microbiol. 84(22), e02085\u2013e02018 (2018).","journal-title":"Appl. Environ. Microbiol."},{"issue":"5","key":"1704_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1128\/AAC.16.5.533","volume":"16","author":"NA Curtis","year":"1979","unstructured":"Curtis, N. A., Orr, D., Ross, G. W. & Boulton, M. G. Affinities of penicillins and cephalosporins for the penicillin-binding proteins of Escherichia coli K-12 and their antibacterial activity. Antimicrob. Agents Chemother. 16(5), 533\u2013539 (1979).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"1704_CR41","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1093\/jac\/41.4.435","volume":"41","author":"T Horii","year":"1998","unstructured":"Horii, T., Kobayashi, M., Sato, K., Ichiyama, S. & Ohta, M. An in-vitro study of carbapenem-induced morphological changes and endotoxin release in clinical isolates of gram-negative bacilli. J. Antimicrob. Chemother. 41(4), 435\u2013442 (1998).","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"1704_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0463.2009.02563.x","volume":"118","author":"L KONG K-F, Schneper","year":"2010","unstructured":"KONG K-F, Schneper, L. & Mathee, K. Beta-lactam antibiotics: From antibiosis to resistance and bacteriology. Apmis 118(1), 1\u201336 (2010).","journal-title":"Apmis"},{"issue":"1","key":"1704_CR43","doi-asserted-by":"publisher","first-page":"01454","DOI":"10.1128\/aac","volume":"62","author":"A Ito","year":"2018","unstructured":"Ito, A. et al. In vitro antibacterial properties of cefiderocol, a novel siderophore cephalosporin, against Gram-negative bacteria. Antimicrob. Agents Chemother. 62(1), 01454\u201301417. https:\/\/doi.org\/10.1128\/aac (2018).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"1704_CR44","doi-asserted-by":"publisher","first-page":"5806","DOI":"10.1128\/AAC.02877-15","volume":"60","author":"JM Regeimbal","year":"2016","unstructured":"Regeimbal, J. M. et al. Personalized therapeutic cocktail of wild environmental phages rescues mice from Acinetobacter baumannii wound infections. Antimicrob. Agents Chemother. 60(10), 5806\u20135816 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1704_CR45","unstructured":"Exner, M. et al. Antibiotic resistance: what is so special about multidrug-resistant Gram-negative bacteria? GMS hygiene and infection control 2017;12."},{"issue":"10","key":"1704_CR46","doi-asserted-by":"publisher","first-page":"e0206278","DOI":"10.1371\/journal.pone.0206278","volume":"13","author":"P Manohar","year":"2018","unstructured":"Manohar, P., Tamhankar, A. J., Lundborg, C. S. & Ramesh, N. Isolation, characterization and in vivo efficacy of Escherichia phage myPSH1131. Plos One 13(10), e0206278 (2018).","journal-title":"Plos One"},{"key":"1704_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12866-020-01833-4","volume":"20","author":"BS Gudlavalleti","year":"2020","unstructured":"Gudlavalleti, B. S. et al. Whole genome sequencing identifies an allele responsible for clear vs. turbid plaque morphology in a mycobacteriophage. BMC Microbiol. 20, 1\u20138 (2020).","journal-title":"BMC Microbiol."},{"issue":"10","key":"1704_CR48","doi-asserted-by":"publisher","first-page":"e01821","DOI":"10.1128\/jvi.01821-23","volume":"98","author":"G Valencia-Toxqui","year":"2024","unstructured":"Valencia-Toxqui, G. & Ramsey, J. How to introduce a new bacteriophage on the block: A short guide to phage classification. J. Virol. 98(10), e01821\u2013e01823 (2024).","journal-title":"J. Virol."},{"issue":"4","key":"1704_CR49","doi-asserted-by":"publisher","first-page":"e000036","DOI":"10.1099\/acmi.0.000036","volume":"1","author":"N Ramesh","year":"2019","unstructured":"Ramesh, N., Archana, L., Madurantakam Royam, M., Manohar, P. & Eniyan, K. Effect of various bacteriological media on the plaque morphology of Staphylococcus and Vibrio phages. Access. Microbiol. 1(4), e000036 (2019).","journal-title":"Access. Microbiol."},{"key":"1704_CR50","unstructured":"Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Edition 31 (Clinical and Laboratory Standards Institute Wayne, PA, 2021)."},{"issue":"9","key":"1704_CR51","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.resmic.2018.05.010","volume":"169","author":"T Tkhilaishvili","year":"2018","unstructured":"Tkhilaishvili, T. et al. Real-time assessment of bacteriophage T3-derived antimicrobial activity against planktonic and biofilm-embedded Escherichia coli by isothermal microcalorimetry. Res. Microbiol. 169(9), 515\u2013521 (2018).","journal-title":"Res. Microbiol."},{"issue":"6","key":"1704_CR52","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/v14061340","volume":"14","author":"R Fanaei Pirlar","year":"2022","unstructured":"Fanaei Pirlar, R. et al. Novel bacteriophage specific against Staphylococcus epidermidis and with antibiofilm activity. Viruses 14(6), 1340 (2022).","journal-title":"Viruses"},{"issue":"4","key":"1704_CR53","doi-asserted-by":"publisher","first-page":"e0231389","DOI":"10.1371\/journal.pone.0231389","volume":"15","author":"S Karbysheva","year":"2020","unstructured":"Karbysheva, S. et al. Comparison of sonication with chemical biofilm dislodgement methods using chelating and reducing agents: Implications for the Microbiological diagnosis of implant associated infection. Plos One 15(4), e0231389 (2020).","journal-title":"Plos One"},{"issue":"9","key":"1704_CR54","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.clinthera.2019.07.006","volume":"41","author":"C Sanabria","year":"2019","unstructured":"Sanabria, C. et al. Effect of cefiderocol, a siderophore cephalosporin, on QT\/QTc interval in healthy adult subjects. Clin. Ther. 41(9), 1724\u20131736 (2019). e4.","journal-title":"Clin. Ther."},{"issue":"3","key":"1704_CR55","doi-asserted-by":"publisher","first-page":"02163","DOI":"10.1128\/aac","volume":"62","author":"Y Saisho","year":"2018","unstructured":"Saisho, Y., Katsube, T., White, S., Fukase, H. & Shimada, J. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-negative bacteria, in healthy subjects. Antimicrob. Agents Chemother. 62(3), 02163\u201302117. https:\/\/doi.org\/10.1128\/aac (2018).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1704_CR56","doi-asserted-by":"publisher","unstructured":"Matsumoto, S. et al. Efficacy of Cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics. Antimicrob. Agents Chemother. 61(9). https:\/\/doi.org\/10.1128\/aac (2017). 00700\u2009\u2013\u200917.","DOI":"10.1128\/aac"},{"issue":"5","key":"1704_CR57","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jcph.841","volume":"57","author":"T Katsube","year":"2017","unstructured":"Katsube, T. et al. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment. J. Clin. Pharmacol. 57(5), 584\u2013591 (2017).","journal-title":"J. Clin. Pharmacol."},{"issue":"11","key":"1704_CR58","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41429-024-00762-y","volume":"77","author":"R Kriz","year":"2024","unstructured":"Kriz, R. et al. In vitro resistance development gives insights into molecular resistance mechanisms against Cefiderocol. J. Antibiot. 77(11), 757\u2013767 (2024).","journal-title":"J. Antibiot."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01704-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01704-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T19:03:13Z","timestamp":1747422193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-01704-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1704"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-01704-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17105"}}